Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Accera logo — Pioneering breakthroughs in neurodegenerative therapies for...

Accera

Pioneering breakthroughs in neurodegenerative therapies for Alzheimer’s, Parkinson’s, and age-related memory impairment.

Founded 2001 11-50 employees Series Unknown Total: $196.22M Biotechnology, Health Care +1

General Information

Company Name Accera
Founded Year 2001
Founders / Decision Makers
Team member
Employees 11-50
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series Unknown
Social

Get notified when Accera moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Accera

Accera, established in 2001 and based in Broomfield, Colorado, is a pioneering biotechnology firm in the fields of neurodegenerative therapies for Alzheimer’s, Parkinson’s, and age-related memory impairment. The company is focused on the discovery and development of therapeutic drugs aimed at neurodegenerative diseases. Their flagship innovation, Ketasyn, is a molecule intended to address conditions such as Alzheimer's, Parkinson's, and age-related memory impairment. Accera recently received a significant $50.00M in a Venture Round investment on 04 October 2018, with Inventages and Wilmar International as the participating investors. The company’s dedication to addressing critical unmet medical needs in the neurodegenerative space has attracted notable support from leading investors.

Taxonomy: neurodegenerative diseases, therapeutic drugs, Alzheimer's, Parkinson's, memory impairment, Ketasyn, drug discovery, drug development

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• 2
Investor
•••• •••• 		04 Oct 2018
Venture Round •••••• - 26 Mar 2018
Private Equity Round •••••• - 25 Oct 2013
Series D •••••• 3
Investor
•••• •••• 		03 Jan 2011
Series C •••••• 2
Investor
•••• •••• 		12 Nov 2008

View All 7 Funding Rounds

Accera Alternatives & Competitors

Accera vs
Congruence Medical Solutions
Congruence Medical Solutions United States

Addressing compelling needs in injectable drug delivery

8 employees
Accera vs
National Drug Screening, Inc.
National Drug Screening, Inc. United States

Drug and alcohol testing programs for large and small employers.

21 employees
Biotechnology, Health Care
Accera vs
Bostal Drug Delivery
Bostal Drug Delivery

Innovative drug delivery solutions enhancing the development and improvement of pharmaceuticals sinc...

Series B
Biotechnology, Health Care

FAQ About Accera

Pioneering breakthroughs in neurodegenerative therapies for Alzheimer’s, Parkinson’s, and age-related memory impairment.
Accera was founded in 2001.
Accera operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
Accera has approximately 11-50 employees.
Accera has completed 7 funding rounds, raising a total of $196.22M. The latest funding stage is Series Unknown.
Top alternatives and competitors to Accera include Congruence Medical Solutions, National Drug Screening, Inc., Bostal Drug Delivery, METiS Pharmaceuticals, Forensic Fluids Laboratories. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Accera and Congruence Medical Solutions are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Accera and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes